CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Metformin XRWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug530 Cash transfer Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011236 Prediabetic State NIH 1.00
D050197 Atherosclerosis NIH 1.00

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002621 Atherosclerosis HPO 1.00

There is one clinical trial.

Clinical Trials

1 CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)

This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pre-diabetes and heart or blood vessel problems.

NCT02915198 Prediabetic State Atherosclerosis Metformin Drug: Metformin XR Drug: Placebo
MeSH:Atherosclerosis Prediabetic State
HPO:Atherosclerosis Type IV atherosclerotic lesion

Primary Outcomes

Description: The primary outcome measure is the time to first occurrence of death, non-fatal myocardial infarction or stroke, hospitalization for unstable angina with objective evidence of acute myocardial ischemia, or coronary revascularization driven by acute or progressive symptoms.

Measure: Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization

Time: through study completion, an average of 4.5 years

Secondary Outcomes

Description: Time to first occurrence of death, myocardial infarction, or stroke Time to first occurrence of a primary endpoint event, peripheral arterial disease event, or hospitalization for congestive heart failure Cumulative incidence of all components of the primary endpoint, including recurrent or multiple events in the same participant Cumulative incidence and time to first occurrence of each component of the primary outcome measure, peripheral arterial disease events, and hospitalization for congestive heart failure

Measure: Time in days to Cardiovascular Outcomes

Time: through study completion, an average of 4.5 years

Description: Time to new or recurrent diagnosis of a malignancy or death from a malignancy

Measure: Time in days to Oncologic Outcome

Time: through study completion, an average of 4.5 years

Description: Time to new diagnosis of type 2 diabetes (ADA criteria)

Measure: Time in days to Diabetes Outcome

Time: through study completion, an average of 4.5 years

Related HPO nodes (Using clinical trials)

HP:0002621: Atherosclerosis
Genes 90
ZNF687 CYP27A1 BSCL2 GGCX ACTA2 NPC2 SERPIND1 LOX ENG KCNJ5 LDLR SMAD4 LMNA ESR1 GGCX SC5D PRKG1 SMPD1 ABCA1 WRN LCAT CSF2RB SMAD3 ABCC6 NOTCH3 MFAP5 TGFBR3 SMPD1 CYP7A1 ABCG8 LMNA ACTA2 ABCA1 CEP19 ALMS1 CAV1 LMNA APOA5 LOX TGFBR2 ELN APOE XYLT1 ABCA1 LDLRAP1 MYLK ABCC6 TGFB3 BANF1 LMNA ANGPTL6 PCSK9 ENPP1 LDLRAP1 CSF2RA FOS APOB TNXB APOB MAT2A FBN1 PPARG ZMPSTE24 LMNA LMNA AGXT COL3A1 LMNA AGPAT2 TGFBR1 TGFB2 ABCG5 GLB1 SMPD1 LMNA XYLT2 FOXE3 THSD1 MYH11 PPARG ANTXR1 MYH11 CAVIN1 LIPC ABCG8 MYH11 NPC1 LCAT ASAH1 HGD
Protein Mutations 3
G21210A V167F V617F
SNP 7
rs1024611 rs1051931 rs10757274 rs10757278 rs16874954 rs1799724 rs2383206
HP:0002635: Type IV atherosclerotic lesion
Genes 1
APOE
Protein Mutations 0
SNP 0